WHO Grade III Glioma
14
8
12
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (14)
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Targeted Pediatric High-Grade Glioma Therapy
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Mind-Body Intervention in Glioma Couples
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
Combination Therapy for the Treatment of Diffuse Midline Gliomas
Study of Olutasidenib and Temozolomide in HGG
Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers